Literature DB >> 20156153

Pretreatment by hyperoxia--a tool to reduce ischaemia-reperfusion injury in the myocardium.

Inga Karu1, Peeter Tähepõld, Arno Ruusalepp, Joel Starkopf.   

Abstract

Atherosclerosis leads to narrowing and occlusion of coronary arteries, resulting in inadequate oxygen supply for maintenance of normal oxidative metabolism. To avoid profound ischaemia and subsequent necrosis of cardiomyocytes, blood flow has to be restored by means of thrombolysis, percutaneous coronary intervention, or surgical revascularisation. Besides restoring oxygen supply to the cells, introduction of molecular oxygen to the ischaemic tissue results in a spectrum of unfavourable events, termed altogether as reperfusion injury. Exposure to hyperoxia for a limited time before ischaemia induces a low-grade oxidative stress and evokes an (ischaemic) preconditioning-like effect in the myocardium, which protects the heart from subsequent injury. This review addresses the effects of pretreatment by hyperoxia both in experimental and clinical setting.

Entities:  

Mesh:

Year:  2010        PMID: 20156153     DOI: 10.2174/157488410791110788

Source DB:  PubMed          Journal:  Curr Clin Pharmacol        ISSN: 1574-8847


  3 in total

1.  Effects of 60 minutes of hyperoxia followed by normoxia before coronary artery bypass grafting on the inflammatory response profile and myocardial injury.

Authors:  Inga Karu; Peeter Tähepõld; Arno Ruusalepp; Kersti Zilmer; Mihkel Zilmer; Joel Starkopf
Journal:  J Negat Results Biomed       Date:  2012-09-14

2.  Rosuvastatin relieves myocardial ischemia/reperfusion injury by upregulating PPAR‑γ and UCP2.

Authors:  Ling Wang; Rong Lin; Langtao Guo; Meiman Hong
Journal:  Mol Med Rep       Date:  2018-05-23       Impact factor: 2.952

3.  Attenuation of the Na/K‑ATPase/Src/ROS amplification signaling pathway by astaxanthin ameliorates myocardial cell oxidative stress injury.

Authors:  Xuefeng Qu; Zhouyi Zhang; Wenli Hu; Minhan Lou; Bingzhong Zhai; Song Mei; Zhihang Hu; Lijing Zhang; Dongying Liu; Zhen Liu; Jianguo Chen; Yin Wang
Journal:  Mol Med Rep       Date:  2020-10-19       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.